Study of the durability of the triple antiretroviral regimens;Estudio de la durabilidad de los regímenes antirretrovirales con tres fármacos

Medicina Clinica

Volumn 122, Issue 18, 2004, Pages 693-695

  Martínez Sesmero, José Manuel ^a   Sánchez Rubio Ferrández, Javier ^a   Ontañón Nasarre, Ana ^a   Ibáñez Heras, Nuria ^a   Montojo Guillén, Cristóbal ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Anti HIV agents; Antiretroviral; Effectiveness; HIV infection; Patient care; Survival

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CALCULATION; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE DURATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

EID: 2942534220     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062167     Document Type: Article

References (10)

1. Palella FJJ, Delaney KM, Morman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60.
2. Murphy R. New antiretroviral drugs. Part I; PI's. Aids Clin Care 1999;11:35-7.
3. Murphy R. New antiretroviral drugs. Part II; NR-TI's; NNRTI's and beyond. Aids Clin Care 1999;11:50-4.
4. a ed., Madrid: Facultad de Medicina Universidad Autónoma, 2001.
5. a Ed. Barcelona: Signo, 1998.
6. Jonson NE. Using epidemiologic principles to desing outcomes assessments. Formulary 2000;35:765-9.
7. Turner BJ. Adherence to antirretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2):143-51.
8. GESIDA-SEFH. Estudio sociosanitarioantropológico y prospectivo DELPHI. Infección por VIH y cumplimiento del tratamiento antirretroviral en España. Madrid: Bernard Krief, 1999.
9. Grupo de estudio VIHVIR+. Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España. Med Clin (Barc) 2002;119:721-4.
10. D'Arminio MA, Lepri AC, Rezza G, Antinori A, Pezzotti P, Giocchino A, et al. Insights into the reasons for discontinuation of the first highly active antiretrovirals therapy (HAART) regimen in a cohort of antiretrovirals naïve patients. AIDS 2000;14:499-507.